Literature DB >> 2120125

Restricted accumulation of globotriaosylceramide in the hearts of atypical cases of Fabry's disease.

K Ogawa1, K Sugamata, N Funamoto, T Abe, T Sato, K Nagashima, S Ohkawa.   

Abstract

Immunohistochemical and biochemical analyses of several tissues were performed in two unusual cases of Fabry's disease which showed accumulation of globotriaosylceramide (Gal alpha 1-4Gal beta 1-4 Glc-Cer, Gb3Cer) only in the hearts, but no clinical signs of the disease. Immunohistochemical study revealed that the hearts from our cases (cases no. 1 and 2) contained large amounts of anti-Gb3Cer antibody-positive granules in cytoplasms as in typical Fabry's disease. The contents of accumulated Gb3Cer in the hearts from case no. 1, case no. 2, and a typical Fabry's disease case were approximately 100, 340, and 100 times higher than those from normal controls, respectively. While typical Fabry's diseased kidney and liver contained approximately 40 and 50 times higher amounts of Gb3Cer than did controls, no accumulation of Gb3Cer was observed in kidney and liver of our cases. The only exception was a slight increase of Gb3Cer in kidney of case no. 2 (about two times higher than controls), in which epithelial cells of the glomeruli but not of other types of cells were positively stained by anti-Gb3Cer antibody. Case no. 1 kidney and liver were not stained by the antibody. The glomerular endothelium and epithelium, tubular epithelium, smooth muscle of renal arteries, and several hepatocytes were Gb3Cer-positive in the typical Fabry's disease case. The involvements of our cases differed distinctly from the typical Fabry's disease case.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2120125     DOI: 10.1016/0046-8177(90)90258-7

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

1.  Cellular and tissue localization of globotriaosylceramide in Fabry disease.

Authors:  Hasan Askari; Christine R Kaneski; Cristina Semino-Mora; Priya Desai; Agnes Ang; David E Kleiner; Lorah T Perlee; Martha Quezado; Linda E Spollen; Brandon A Wustman; Raphael Schiffmann
Journal:  Virchows Arch       Date:  2007-08-03       Impact factor: 4.064

Review 2.  Gene therapy for Fabry disease.

Authors:  C Siatskas; J A Medin
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

3.  Sisters with atypical Fabry's disease with complete atrioventricular block.

Authors:  Y Doi; G Toda; K Yano
Journal:  Heart       Date:  2003-01       Impact factor: 5.994

4.  Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype.

Authors:  Satoshi Ishii; Shoichiro Nakao; Reiko Minamikawa-Tachino; Robert J Desnick; Jian-Qiang Fan
Journal:  Am J Hum Genet       Date:  2002-02-04       Impact factor: 11.025

5.  Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population.

Authors:  Robert Dobrovolny; Lenka Dvorakova; Jana Ledvinova; Sudheera Magage; Jan Bultas; Jean C Lubanda; Milan Elleder; Debora Karetova; Marketa Pavlikova; Martin Hrebicek
Journal:  J Mol Med (Berl)       Date:  2005-04-02       Impact factor: 4.599

6.  Unexplained left ventricular hypertrophy: consider a diagnosis of Fabry's disease.

Authors:  G E Linthorst; A C Vedder; B J Bouma; L R C Dekker; C E M Hollak
Journal:  Neth Heart J       Date:  2006-03       Impact factor: 2.380

Review 7.  Lysosomal storage diseases.

Authors:  Carlos R Ferreira; William A Gahl
Journal:  Transl Sci Rare Dis       Date:  2017-05-25

Review 8.  Cardiac abnormalities in Anderson-Fabry disease and Fabry's cardiomyopathy.

Authors:  R P Morrissey; K J Philip; E R Schwarz
Journal:  Cardiovasc J Afr       Date:  2011 Jan-Feb       Impact factor: 1.167

Review 9.  The Cardiovascular Phenotype in Fabry Disease: New Findings in the Research Field.

Authors:  Daniela Sorriento; Guido Iaccarino
Journal:  Int J Mol Sci       Date:  2021-01-29       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.